[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100396593":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":37,"collaborators":7,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":54,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Johann Wolfgang Goethe University Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Cardiac Imaging","Subjects undergo CMR study with contrast agent (gadobutrol 0.1 mmol\u002Fkg; mapping, volumes, function, strain and LGE); transthoracic echocardiography, blood sampling and cardiopulmonary exercise testing.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Valentina O Puentmann","CONTACT","+4969 630184491","cvi-studien@unimedizin-ffm.de",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":23,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"University Hospital Frankfurt","RECRUITING","Frankfurt am Main","Hesse","Germany","DE",{"type":28,"coordinates":29},"Point",[30,31],8.68417,50.11552,{"lat":31,"lon":30},[34],{"name":35,"role":16,"phone":36,"phoneExt":7,"email":18},"Valentina O Puentmann, MD, PhD","+4969186760",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Valentina Puentmann","Priv Doz Dr Dr","100396593","improving-cardiovascular-risk-stratification-using-t1-mapping-in-general-population-100396593",false,"NCT04444128","IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION","IMPReSSION","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. 18 years of age and over\n3. Absence of a valid clinical indication for CMR, and\u002For known or clinically relevant cardiac disease\n\nExclusion Criteria:\n\n* accepted contraindications for a contrast-enhanced CMR study (in line with MRI safety and SmPC for contrast agent)",true,"ALL","18 Years",{"count":52,"type":53},6000,"ESTIMATED","5 Years","OBSERVATIONAL","Magnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles, the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy, relationships with clinical characteristics, cardiovascular risk factors, routine cardiac imaging parameters, and prognosis. A further unknown relates to separation between healthy myocardium and subclinical disease in subgroups of patients with suspected cardiac involvement. Examples include patients with possible inflammation, such as in patients with a recent COVID-19 infection or vaccination. Anticipated recruitment of a total of 3000 subjects, with 1500 subjects per field strength (1.5 and 3.0 Tesla).",[58,59,60,61,62],"Myocarditis","Heart Failure","Myocardial Fibrosis","Vascular Inflammation","Long COVID Syndrome",[64,65,66],"Inflammation","Remodeling","vascular inflammation","2026-01-02",{"date":69,"type":70},"2026-01-06","ACTUAL",{"date":72,"type":70},"2016-11-15",{"date":74,"type":53},"2030-06-30",{"name":5,"class":6},1]